What we are watching
Top 10 by severity and recency
Reimbursement watchlist
Live LCD rewrites on cellular and tissue-based products are reshaping coverage.
Multiple Medicare Administrative Contractors are revising LCDs for skin substitute grafts and cellular & tissue-based products (CTPs) used on chronic wounds. Coverage shifts here move billions in run-rate revenue across publicly traded wound-care issuers. AimwellBio's CMS LCD ingest is in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as the indexer comes online.
Monitored issuers and operators
Volume & cadence of public disclosure
Saudi Arabia · Vision 2030
Diabetic foot disease is a Vision 2030 health priority — and the verification problem is national.
The Kingdom of Saudi Arabia carries one of the highest diabetes prevalence rates among adults globally, with diabetic foot ulcer progression to lower-extremity amputation a stated reduction target inside the Ministry of Health's Vision 2030 health-system transformation goals. Decisions of this scale — coverage policy, formulary, capital procurement of advanced wound therapies — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer.
AimwellBio is built for that layer. Every signal in this report carries its origin URL and fetch timestamp. Every claim is reproducible. Every gap is disclosed.
Methodology
This report is generated from a live ingest pipeline (tools/scout-ingest). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated —. Every signal carries source URL and fetch timestamp; click any card to view origin.
Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.
Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA.